Barcelona, Spain: Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour’s response to chemotherapy and, therefore, the patient’s ultimate likelihood of survival. In research presented today (Tuesday) at the European Cancer Conference (ECCO 14) in Barcelona, Dr Vinod Ganju reported that when the scanning procedure was used to measure the accumulation of radioactive glucose fluorodeoxyglucose (FDG) in tumour tissue from patients with locally-advanced breast cancer before and after preoperative chemotherapy, women who had the highest accumulation at the beginning and who then had the highest percentage drop in accumulation after four cycles of chemotherapy were more likely to have a complete response to their treatment i.e. no tumour cells remaining in the final tumour resection specimen. However, measurements taken using mammography or ultrasound were not able to predict a pathological response accurately
